Passenger mutations as a target for the personalized therapy of cancer
- Published
- Accepted
- Subject Areas
- Oncology, Medical Genetics, Computational Science
- Keywords
- passenger mutations, personalized therapy, data mining, drug repositioning
- Copyright
- © 2018 Monticelli et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
- Cite this article
- 2018. Passenger mutations as a target for the personalized therapy of cancer. PeerJ Preprints 6:e27338v1 https://doi.org/10.7287/peerj.preprints.27338v1
Abstract
The American FDA approved the first comprehensive NGS diagnostic assay for cancer at the end of 2017, leading the way to personalised therapy of cancer and the massive employ of bioinformatics (https://www.fda.gov/downloads/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ ucm584603.pdf ).
In NGS-detected genes from cancer patients, driver and passenger mutations can be distinguished. The former provides a proliferative advantage to cancer cells and are commonly found, the latter do not provide proliferative fitness and are different in different patients. However, some passenger mutations might occur in genes involved in metabolism and could be mildly deleterious for cancer cells. Such deleteriousness could be increased using a specific inhibitor of the mutated protein product. A personalized therapy of cancer could address both driver and passenger mutations. To evaluate to which extent it is possible to address passenger mutations for the cure of cancers, we built a gene/ inhibitor list, crossing DrugBank, a database that combines detailed drug data with comprehensive drug target information, with COSMIC, the catalogue of somatic mutations in cancer. First, we obtained the approved drugs annotated as inhibitors from DrugBank, and the genes encoding their target proteins. We then looked for these genes in COSMIC, to check how many missense mutations have been detected in cancer patient genomes.
Author Comment
“This is an abstract which has been accepted for the BBCC2018 Conference”